2024
Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease
McMillan C, Li D, Mohamed G, Alsadoun D, Almohsen L, Gaidos J, Proctor D, Al-Bawardy B. Longer Colonoscopy Withdrawal Time Is Associated With the Detection of Visible Dysplasia in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2024, 6: otae020. PMID: 38585555, PMCID: PMC10998460, DOI: 10.1093/crocol/otae020.Peer-Reviewed Original ResearchColonoscopy withdrawal timeHigh-definition white light colonoscopyInflammatory bowel diseaseWhite light colonoscopyVisible dysplasiaBowel diseasePersonal historyWithdrawal timeAssociated with detectionEndoscopic healingAdenoma detectionDysplasia detectionDysplasia groupRetrospective studyAdult patientsInvisible dysplasiaColonoscopyPrimary outcomeDysplasiaMultivariate analysisPatientsIncreasing ageGeneral populationMinutesDiseaseImpact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
Sahyoun L, Fetene J, McMillan C, Protiva P, Al Bawardy B, Gaidos J, Proctor D. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 1654-1660. PMID: 38466459, DOI: 10.1007/s10620-024-08355-3.Peer-Reviewed Original ResearchSevere COVID-19 infectionInflammatory bowel diseaseCOVID-19 infectionIBD flareIBD therapyCOVID-19 treatmentSingle-center retrospective study of adult patientsMethodsA single-center retrospective studyAdvanced therapiesRetrospective study of adult patientsBowel diseaseStudy of adult patientsInflammatory bowel disease therapyDevelopment of severe COVID-19 infectionSevere COVID-19Acute COVID-19Corticosteroid useNo significant differenceNo therapyAdult patientsSupplemental oxygenPrimary outcomeSecondary outcomesTherapyCorticosteroids
2023
S1006 Comparison of Upadacitinib Induction in Tofacitinib Exposed and Naïve Patients With Inflammatory Bowel Disease: A Real World Multi-Center Study
Almomen H, Alomar I, McMillan C, Gaidos J, Proctor D, AlMutairdi A, Al-Bawardy B. S1006 Comparison of Upadacitinib Induction in Tofacitinib Exposed and Naïve Patients With Inflammatory Bowel Disease: A Real World Multi-Center Study. The American Journal Of Gastroenterology 2023, 118: s761-s762. DOI: 10.14309/01.ajg.0000953664.83573.de.Peer-Reviewed Original ResearchOutcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease
Sayed A, Assis D, Silveira M, Deng Y, Ciarleglio M, Gaidos J, Proctor D, Al-Bawardy B. Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease. European Journal Of Gastroenterology & Hepatology 2023, 35: 270-274. PMID: 36708297, DOI: 10.1097/meg.0000000000002510.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisInflammatory bowel diseasePSC-IBDEndoscopic healingTherapy groupAdvanced therapiesClinical remissionBowel diseaseAcute ascending cholangitisRate of cholangitisSmall bowel involvementThird of patientsAscending cholangitisSclerosing cholangitisAdult patientsBowel involvementSecondary outcomesMedian agePrimary outcomeRetrospective studyHigh riskCholangitisPatientsTherapyLarger study
2022
0573 Daytime and Nighttime Sleep and Symptoms of Depression and Anxiety in Adults with Inflammatory Bowel Disease
Conley S, Proctor D, Jeon S, Redeker N. 0573 Daytime and Nighttime Sleep and Symptoms of Depression and Anxiety in Adults with Inflammatory Bowel Disease. Sleep 2022, 45: a252-a252. DOI: 10.1093/sleep/zsac079.570.Peer-Reviewed Original ResearchInflammatory bowel diseaseSymptoms of depressionNighttime sleepSleep qualityAnxious symptomsBowel diseaseSleep durationCross-sectional feasibility studyOutcomes Measurement Information System (PROMIS) measuresTreatment of sleepPresence of depressionPoor sleep qualityInadequate sleep durationNightly sleep durationHealth care providersWrist-worn actigraphsIBD centerModerate effect sizeAutoimmune diseasesPoor sleepMean depressionSleep characteristicsCare providersSleep efficiencyGeneral populationImpact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
Nawaz A, Glick L, Chaar A, Li D, Gaidos J, Proctor D, Al-Bawardy B. Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals Of Gastroenterology 2022, 36: 39-44. PMID: 36593807, PMCID: PMC9756033, DOI: 10.20524/aog.2022.0766.Peer-Reviewed Original ResearchInflammatory bowel diseaseC-reactive proteinAnti-TNF combination therapySteroid-free clinical remissionCombination therapyThiopurine doseDose groupEndoscopic healingClinical remissionBowel diseaseUlcerative colitisCrohn's diseaseTherapeutic doseNormal serum C-reactive proteinAnti-tumor necrosis factorNormal C-reactive proteinSerum C-reactive proteinAnti-drug antibody formationAnti-TNF immunogenicityCohort of patientsLow-dose groupSignificant differencesSecondary outcomesPrimary outcomeClinical outcomesEffect of obesity on vedolizumab response in inflammatory bowel disease
Levine LJ, Gaidos JKJ, Proctor DD, Viana AV, Al-Bawardy B. Effect of obesity on vedolizumab response in inflammatory bowel disease. Annals Of Gastroenterology 2022, 35: 275-280. PMID: 35599926, PMCID: PMC9062841, DOI: 10.20524/aog.2022.0699.Peer-Reviewed Original ResearchBody mass indexInflammatory bowel diseaseSteroid-free clinical remissionNon-obese groupC-reactive proteinObese groupCRP normalizationEndoscopic remissionIBD patientsBowel diseaseDose escalationNormal serum C-reactive proteinMedian body mass indexSerum C-reactive proteinHigher body mass indexEndoscopic remission ratesEffect of obesityVedolizumab discontinuationVedolizumab levelsClinical remissionMedian followRemission rateSecondary outcomesMedian agePrimary outcome
2021
The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services
Hussain N, Proctor D, Al-Bawardy B. The Impact of Inflammatory Bowel Disease Clinic On-site Vaccination Services. Crohn's & Colitis 360 2021, 3: otab067. PMID: 36777277, PMCID: PMC9802036, DOI: 10.1093/crocol/otab067.Peer-Reviewed Original ResearchInflammatory bowel diseaseClinic BIBD clinicHerpes zosterClinic AVaccination servicesSite vaccinationVaccine discussionsInflammatory bowel disease clinicHepatitis B vaccinationVaccine-preventable diseasesLow vaccination ratesCompletion ratesB vaccinationIBD patientsIBD physiciansVaccine completionBowel diseaseDisease clinicClinic 1Retrospective studyVaccination ratesDiscussion rateComprehensive careImmunization ratesNovel and Emerging Therapies for Inflammatory Bowel Disease
Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Frontiers In Pharmacology 2021, 12: 651415. PMID: 33935763, PMCID: PMC8080036, DOI: 10.3389/fphar.2021.651415.BooksInflammatory bowel diseaseBowel diseaseAnti-tumor necrosis factorPotential systemic manifestationsSecondary treatment failureTreatment response ratesJanus kinase inhibitorSelective Janus kinase inhibitorNew therapeutic targetsEmerging TherapiesCurrent biologicsIntestinal inflammationSystemic manifestationsUlcerative colitisCrohn's diseaseTreatment failureSafety profileNecrosis factorTherapeutic targetResponse rateDiseaseKinase inhibitorsTarget agentsInhibitorsTolerabilityTHE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS
Li M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Gastroenterology 2021, 160: s62. DOI: 10.1053/j.gastro.2021.01.159.Peer-Reviewed Original ResearchTHE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS
Li M, Khan S, Proctor D, Gaidos J, Al-Bawardy B. THE SAFETY, TOLERABILITY, AND EFFECTIVENESS OF BIOLOGICS/SMALL MOLECULE THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND CIRRHOSIS. Inflammatory Bowel Diseases 2021, 27: s45-s46. DOI: 10.1093/ibd/izaa347.110.Peer-Reviewed Original ResearchInflammatory bowel diseaseBiologic agentsAdverse eventsSmall molecule therapiesClinical remissionMucosal healingBowel diseaseConcomitant cirrhosisConcomitant corticosteroid therapyDifferent biologic agentsPrimary sclerosing cholangitisQuarter of patientsCohort of patientsEffectiveness of biologicsSmall molecule agentsConcomitant thiopurinesCorticosteroid therapyIBD patientsIBD therapyCertolizumab pegolSclerosing cholangitisAdult patientsBiologic therapyInfusion reactionsSecondary outcomes
2020
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritisS0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel Disease
Hussain N, Proctor D, Ruggiero E, Al-Bawardy B. S0709 IBD Clinic On-Site Vaccination Services and Vaccination Completion Rates in Patients With Inflammatory Bowel Disease. The American Journal Of Gastroenterology 2020, 115: s356-s356. DOI: 10.14309/01.ajg.0000704884.71749.ca.Peer-Reviewed Original ResearchS0830 The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study
Ramos G, Dimopoulos C, McDonald N, Janssens L, Hung K, Proctor D, Ruggiero E, Bruning D, Faubion W, Raffals L, Loftus E, Al-Bawardy B. S0830 The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. The American Journal Of Gastroenterology 2020, 115: s427-s428. DOI: 10.14309/01.ajg.0000705368.24314.98.Peer-Reviewed Original ResearchThe Feasibility of Measuring Sleep and Circadian Characteristics in Adults with Inflammatory Bowel Disease
Conley S, Proctor DD, Lehner V, Jeon S, Redeker NS. The Feasibility of Measuring Sleep and Circadian Characteristics in Adults with Inflammatory Bowel Disease. Western Journal Of Nursing Research 2020, 43: 53-59. PMID: 32517546, PMCID: PMC7704942, DOI: 10.1177/0193945920933926.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseBowel diseaseWrist actigraphyInactive inflammatory bowel diseaseActivity diaryElectronic diarySleep/activitySalivary dim light melatonin onsetDim light melatonin onsetRest-activity rhythmWrist actigraphSaliva collectionMelatonin onsetSleepDiseaseActigraphyCircadian characteristicsAdult participantsAdultsCircadian rhythmSalivaDiaryParticipantsRhythmYearsSleep Characteristics and Rest–Activity Rhythms Are Associated with Gastrointestinal Symptoms Among Adults with Inflammatory Bowel Disease
Conley S, Jeon S, Lehner V, Proctor DD, Redeker NS. Sleep Characteristics and Rest–Activity Rhythms Are Associated with Gastrointestinal Symptoms Among Adults with Inflammatory Bowel Disease. Digestive Diseases And Sciences 2020, 66: 181-189. PMID: 32193859, PMCID: PMC8162988, DOI: 10.1007/s10620-020-06213-6.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseRest-activity rhythmHeartburn/refluxDisease activityGI symptomsSleep characteristicsBowel diseaseGas/bloatingCross-sectional studySpecific sleep characteristicsRAR variablesGastrointestinal symptomsIntra-daily variabilityBackgroundSleep disturbancesSleep efficiencyAimsThe purposeSleep onsetSymptomsAdultsDiseaseRefluxPoor qualityAssociationRhythmRemission
2019
0636 Activity-Rest Patterns and Symptoms in Inflammatory Bowel Disease
Conley S, Jeon S, Lehner V, Proctor D, Redeker N. 0636 Activity-Rest Patterns and Symptoms in Inflammatory Bowel Disease. Sleep 2019, 42: a253-a253. DOI: 10.1093/sleep/zsz067.634.Peer-Reviewed Original ResearchInflammatory bowel diseaseSymptom groupsLow symptom groupActivity-rest patternBedtime melatoninBowel diseaseCo-occurring painSymptoms of fatigueVisual analog scaleBright light therapyLower interdaily stabilityActive diseaseSymptom burdenPROMIS scalesCrohn's diseaseAnalog scaleSleep disturbancesUnpredictable courseActivity-rest rhythmsChronic diseasesAdults 18RemissionLight therapyWrist actigraphySalivary melatonin
2018
Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel Disease
Conley S, Jeon S, Proctor DD, Sandler RS, Redeker NS. Longitudinal Changes in Symptom Cluster Membership in Inflammatory Bowel Disease. Journal Of Nursing Scholarship 2018, 50: 473-481. PMID: 29971936, PMCID: PMC6120775, DOI: 10.1111/jnu.12409.Peer-Reviewed Original ResearchConceptsSymptom cluster membershipInflammatory bowel diseaseSymptom burdenBowel diseaseLower symptom burdenPsychological symptoms groupSymptom management optionsHigh symptom burdenRetrospective longitudinal studyLatent transition analysisActive diseaseClinical factorsPain interferenceColitis FoundationSleep disturbancesCluster membershipHigh burdenMultiple symptomsSymptom groupsPhysical symptomsPsychological symptomsLow burdenSymptom clustersLongitudinal changesSymptoms
2017
Symptom clusters in adults with inflammatory bowel disease
Conley S, Proctor DD, Jeon S, Sandler RS, Redeker NS. Symptom clusters in adults with inflammatory bowel disease. Research In Nursing & Health 2017, 40: 424-434. PMID: 28833284, PMCID: PMC5597486, DOI: 10.1002/nur.21813.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseSymptom burdenBowel diseaseHigh symptom burden groupSymptom clustersOutcomes Measurement Information System (PROMIS) measuresLower symptom burdenHigh symptom burdenActive disease stateLatent class analysisSymptom management interventionsSymptom cluster groupsSymptom cluster membershipClinical factorsCrohn's diseasePain interferenceBurden groupRetrospective studyColitis FoundationSleep disturbancesFemale genderReduced qualityPhysical symptomsPsychological symptomsSymptoms
2016
JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages
Hedl M, Proctor DD, Abraham C. JAK2 Disease-Risk Variants Are Gain of Function and JAK Signaling Threshold Determines Innate Receptor-Induced Proinflammatory Cytokine Secretion in Macrophages. The Journal Of Immunology 2016, 197: 3695-3704. PMID: 27664279, PMCID: PMC5127452, DOI: 10.4049/jimmunol.1600845.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseAnti-inflammatory cytokinesImmune-mediated diseasesOligomerization domain 2Proinflammatory cytokinesMyeloid cellsJAK2 expressionJAK inhibitorsIntestinal myeloid cellsThymic stromal lymphopoietinUlcerative colitis patientsProinflammatory cytokine secretionPattern recognition receptorsHuman myeloid cellsLower JAK2Cell typesColitis patientsBowel diseaseIL-10IL-22Peripheral macrophagesIL-4Cytokine secretionAA carriersDecreased response